| Bioactivity | CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor. | ||||||||||||
| Target | SHIP2 | ||||||||||||
| Invitro | CPDA enhances insulin signaling. | ||||||||||||
| In Vivo | CPDA greatly improves abnormal glucose metabolism in diabetic animals. CPDA improves the abnormal glucose metabolism in db/db mice. | ||||||||||||
| Name | CPDA | ||||||||||||
| CAS | 1415834-63-7 | ||||||||||||
| Formula | C20H15ClF2N2O2 | ||||||||||||
| Molar Mass | 388.80 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). Eur J Med Chem. 2013 Apr;62:649-660. |